<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225549</url>
  </required_header>
  <id_info>
    <org_study_id>D2340C00005</org_study_id>
    <nct_id>NCT01225549</nct_id>
  </id_info>
  <brief_title>The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen</brief_title>
  <acronym>Allergen</acronym>
  <official_title>A Double-blind, Double-dummy, Randomised, Placebo-controlled, 4-way, Crossover, Multi-centre Phase II Study With Budesonide as an Active Control to Evaluate the Efficacy and Safety of 2 Doses of Inhaled AZD5423 Over 7 Days in Patients With Mild Allergic Asthma Challenged With an Inhaled Allergen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma
      challenged with an inhaled allergen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1</measure>
    <time_frame>From Randomization to end of treatment</time_frame>
    <description>LAR was assessed on Day 6 as minimum percentage of FEV1 over 3 to 7 hours based on the analysis of the minimum percentage of FEV1 remaining over 3 to 7 hours post allergen challenge (post AC) compared to pre allergen challenge (pre AC) FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Allergic Response (EAR) by Assessment of Minimum Percentage of FEV1 0-3 h Post Allergen Challenge</measure>
    <time_frame>From Randomization to end of treatment</time_frame>
    <description>Minimum Percentage of FEV1 over 0 to 3 hours post allergen challenge compared to pre allergen challenge FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for FEV1 Over 0-3 and 3-7 h Post Allergen Challenge</measure>
    <time_frame>From Randomization to end of treatment</time_frame>
    <description>AUC was assessed as average percentage of FEV1 remaining 0 to 3 hours and 3 to 7 hours post allergen challenge compared to pre allergen challenge FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway Hyperresponsiveness by Assessment of Methacholine PC20</measure>
    <time_frame>Day 1 (pre-dose)</time_frame>
    <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway Hyperresponsiveness by Assessment of Methacholine PC20</measure>
    <time_frame>Day 5 ([post-dose] pre allergen challenge)</time_frame>
    <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway Hyperresponsiveness by Assessment of Methacholine PC20</measure>
    <time_frame>Day 7 ([post-dose] 24 hours post allergen challenge)</time_frame>
    <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sputum Eosinophils Differentials (Percentage)</measure>
    <time_frame>Day 5 (post dose)</time_frame>
    <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sputum Eosinophils Differentials (Percentage)</measure>
    <time_frame>Day 6 ([post dose] 7 hours post allergen challenge)</time_frame>
    <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sputum Eosinophils Differentials (Percentage)</measure>
    <time_frame>Day 7 ([post dose] 24 hours post allergen challenge)</time_frame>
    <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5423 75ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5423 300ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide 200 microgram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5423</intervention_name>
    <description>Suspension for nebulisation once daily 7 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 200 microgram</intervention_name>
    <description>Dry powder for inhalation twice daily 7 days</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for nebulisation once daily 7 days</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for nebulisation once daily 7 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-60 years of age

          -  Pre-bronchodilatory FEV1 ≥70% of predicted normal allergic asthmatic with a history of
             episodic wheeze

          -  Positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall
             in FEV1 for the early and ≥ 15% for the late response

          -  Positive skin prick test to common aeroallergens

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Any clinically relevant abnormal finding at screening examinations

          -  Smoker or ex-smoker who has stopped smoking &lt; 12 months prior to study start

          -  Worsening of asthma or respiratory infection within 6 weeks from visit 1

          -  Allergen-specific immunotherapy within 6 months prior to visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christer Hultquist</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Mölndal, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=203&amp;filename=D2340C00005.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <results_first_submitted>January 15, 2015</results_first_submitted>
  <results_first_submitted_qc>March 31, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2015</results_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergen Challenge</keyword>
  <keyword>Asthma</keyword>
  <keyword>Inhaled selective glucocorticoid receptor agonist (iSEGRA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from 4 centres in the AllerGen CIC group in Canada.</recruitment_details>
      <pre_assignment_details>Total 27 patients enrolled, 20 (74.1%) patients were randomised to receive a treatment sequence consisting of 4 different treatment in random order. From 20 randomised patients, 18 (90%) patients completed the study and 2 (10%) patients were withdrawn from the study due to consumption of disallowed medication</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ACBP</title>
          <description>AZD5423 75 µg followed by budesonide 200 µg bid followed by AZD5423 300 µg od followed by placebo</description>
        </group>
        <group group_id="P2">
          <title>APBC</title>
          <description>AZD5423 75 µg followed by placebo followed by AZD5423 300 µg od followed by budesonide 200 µg bid</description>
        </group>
        <group group_id="P3">
          <title>BACP</title>
          <description>AZD5423 300 µg od followed by AZD5423 75 µg followed by budesonide 200 µg bid followed by placebo</description>
        </group>
        <group group_id="P4">
          <title>BPCA</title>
          <description>AZD5423 300 µg od followed by placebo followed by budesonide 200 µg bid followed by AZD5423 75 µg</description>
        </group>
        <group group_id="P5">
          <title>CAPB</title>
          <description>Budesonide 200 µg bid followed by AZD5423 75 µg followed by placebo followed by AZD5423 300 µg od</description>
        </group>
        <group group_id="P6">
          <title>CBAP</title>
          <description>Budesonide 200 µg bid followed by AZD5423 300 µg od followed by AZD5423 75 µg followed by placebo</description>
        </group>
        <group group_id="P7">
          <title>CBPA</title>
          <description>Budesonide 200 µg bid followed by AZD5423 300 µg od followed by placebo followed by AZD5423 75 µg</description>
        </group>
        <group group_id="P8">
          <title>PBAC</title>
          <description>Placebo followed by AZD5423 300 µg od followed by AZD5423 75 µg followed by budesonide 200 µg bid</description>
        </group>
        <group group_id="P9">
          <title>PCAB</title>
          <description>Placebo followed by budesonide 200 µg bid followed by AZD5423 75 µg followed by AZD5423 300 µg od</description>
        </group>
        <group group_id="P10">
          <title>PCBA</title>
          <description>Placebo followed by budesonide 200 µg bid followed by AZD5423 300 µg od followed by AZD5423 75 µg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - First Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 - Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 - Second Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4 - Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disallowed medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 5 - Third Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 6 - Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disallowed medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 7 - Fourth Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Total</title>
          <description>Total number of patients randomised and treated in the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" lower_limit="18" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1</title>
        <description>LAR was assessed on Day 6 as minimum percentage of FEV1 over 3 to 7 hours based on the analysis of the minimum percentage of FEV1 remaining over 3 to 7 hours post allergen challenge (post AC) compared to pre allergen challenge (pre AC) FEV1</description>
        <time_frame>From Randomization to end of treatment</time_frame>
        <population>PD Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Late Allergic Response (LAR) by Assessment of Minimum Percentage of FEV1 3-7 Hours Post Allergen Challenge Compared to Pre Allergen Challenge FEV1</title>
          <description>LAR was assessed on Day 6 as minimum percentage of FEV1 over 3 to 7 hours based on the analysis of the minimum percentage of FEV1 remaining over 3 to 7 hours post allergen challenge (post AC) compared to pre allergen challenge (pre AC) FEV1</description>
          <population>PD Analysis set</population>
          <units>Percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.97" lower_limit="73.20" upper_limit="100.00"/>
                    <measurement group_id="O2" value="91.32" lower_limit="76.80" upper_limit="101.60"/>
                    <measurement group_id="O3" value="87.28" lower_limit="56.60" upper_limit="103.20"/>
                    <measurement group_id="O4" value="85.83" lower_limit="69.60" upper_limit="102.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Allergic Response (EAR) by Assessment of Minimum Percentage of FEV1 0-3 h Post Allergen Challenge</title>
        <description>Minimum Percentage of FEV1 over 0 to 3 hours post allergen challenge compared to pre allergen challenge FEV1</description>
        <time_frame>From Randomization to end of treatment</time_frame>
        <population>PD Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Allergic Response (EAR) by Assessment of Minimum Percentage of FEV1 0-3 h Post Allergen Challenge</title>
          <description>Minimum Percentage of FEV1 over 0 to 3 hours post allergen challenge compared to pre allergen challenge FEV1</description>
          <population>PD Analysis set</population>
          <units>Percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.75" lower_limit="41.00" upper_limit="94.00"/>
                    <measurement group_id="O2" value="69.57" lower_limit="41.80" upper_limit="92.60"/>
                    <measurement group_id="O3" value="67.98" lower_limit="41.60" upper_limit="92.40"/>
                    <measurement group_id="O4" value="69.30" lower_limit="35.20" upper_limit="92.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for FEV1 Over 0-3 and 3-7 h Post Allergen Challenge</title>
        <description>AUC was assessed as average percentage of FEV1 remaining 0 to 3 hours and 3 to 7 hours post allergen challenge compared to pre allergen challenge FEV1</description>
        <time_frame>From Randomization to end of treatment</time_frame>
        <population>PD Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for FEV1 Over 0-3 and 3-7 h Post Allergen Challenge</title>
          <description>AUC was assessed as average percentage of FEV1 remaining 0 to 3 hours and 3 to 7 hours post allergen challenge compared to pre allergen challenge FEV1</description>
          <population>PD Analysis set</population>
          <units>Percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC over 0-3 (Average EAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.82" lower_limit="64.10" upper_limit="95.25"/>
                    <measurement group_id="O2" value="83.71" lower_limit="65.70" upper_limit="96.68"/>
                    <measurement group_id="O3" value="81.90" lower_limit="56.50" upper_limit="93.90"/>
                    <measurement group_id="O4" value="82.26" lower_limit="57.10" upper_limit="97.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC over 3-7 (Average LAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.30" lower_limit="87.62" upper_limit="104.67"/>
                    <measurement group_id="O2" value="96.53" lower_limit="85.70" upper_limit="103.93"/>
                    <measurement group_id="O3" value="93.39" lower_limit="69.69" upper_limit="107.34"/>
                    <measurement group_id="O4" value="92.50" lower_limit="80.77" upper_limit="106.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Airway Hyperresponsiveness by Assessment of Methacholine PC20</title>
        <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
        <time_frame>Day 1 (pre-dose)</time_frame>
        <population>PD Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Hyperresponsiveness by Assessment of Methacholine PC20</title>
          <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
          <population>PD Analysis set</population>
          <units>mg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.560" lower_limit="0.11" upper_limit="32.00"/>
                    <measurement group_id="O2" value="1.651" lower_limit="0.14" upper_limit="36.80"/>
                    <measurement group_id="O3" value="1.688" lower_limit="0.08" upper_limit="17.75"/>
                    <measurement group_id="O4" value="1.538" lower_limit="0.07" upper_limit="53.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Airway Hyperresponsiveness by Assessment of Methacholine PC20</title>
        <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
        <time_frame>Day 5 ([post-dose] pre allergen challenge)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Hyperresponsiveness by Assessment of Methacholine PC20</title>
          <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
          <units>mg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.755" lower_limit="0.13" upper_limit="32.00"/>
                    <measurement group_id="O2" value="2.693" lower_limit="0.26" upper_limit="64.00"/>
                    <measurement group_id="O3" value="2.477" lower_limit="0.19" upper_limit="18.70"/>
                    <measurement group_id="O4" value="2.034" lower_limit="0.09" upper_limit="53.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Airway Hyperresponsiveness by Assessment of Methacholine PC20</title>
        <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
        <time_frame>Day 7 ([post-dose] 24 hours post allergen challenge)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Airway Hyperresponsiveness by Assessment of Methacholine PC20</title>
          <description>The methacholine challenge was performed on Day 1 (pre dose), Day 5 ([post dose] pre AC), and Day 7 ([post dose] 24 hours post AC)</description>
          <units>mg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.017" lower_limit="0.21" upper_limit="32.00"/>
                    <measurement group_id="O2" value="2.007" lower_limit="0.15" upper_limit="45.89"/>
                    <measurement group_id="O3" value="1.666" lower_limit="0.06" upper_limit="17.19"/>
                    <measurement group_id="O4" value="1.214" lower_limit="0.06" upper_limit="35.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Sputum Eosinophils Differentials (Percentage)</title>
        <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
        <time_frame>Day 5 (post dose)</time_frame>
        <population>PD Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Sputum Eosinophils Differentials (Percentage)</title>
          <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
          <population>PD Analysis set</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.891" spread="8.375"/>
                    <measurement group_id="O2" value="-3.2" spread="9.162"/>
                    <measurement group_id="O3" value="-1.825" spread="4.342"/>
                    <measurement group_id="O4" value="-0.016" spread="1.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Sputum Eosinophils Differentials (Percentage)</title>
        <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
        <time_frame>Day 6 ([post dose] 7 hours post allergen challenge)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Sputum Eosinophils Differentials (Percentage)</title>
          <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.633" spread="6.011"/>
                    <measurement group_id="O2" value="0.592" spread="9.658"/>
                    <measurement group_id="O3" value="7.500" spread="11.800"/>
                    <measurement group_id="O4" value="12.333" spread="14.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Sputum Eosinophils Differentials (Percentage)</title>
        <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
        <time_frame>Day 7 ([post dose] 24 hours post allergen challenge)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - 75ug AZD5423</title>
            <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - 300ug AZD5423</title>
            <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - 2x200ug Budesonide</title>
            <description>200µg budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - Placebo</title>
            <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Sputum Eosinophils Differentials (Percentage)</title>
          <description>The change form baseline in percentage of sputum eosinophils was assessed on Day 5 (post dose) ,Day 6 ([post dose] 7 hours post allergen challenge) and Day 7 ([post dose] 24 hours post allergen challenge)</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.688" spread="8.230"/>
                    <measurement group_id="O2" value="2.286" spread="15.417"/>
                    <measurement group_id="O3" value="6.967" spread="11.697"/>
                    <measurement group_id="O4" value="5.634" spread="5.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1 - 75ug AZD5423</title>
          <description>75ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 - 300ug AZD5423</title>
          <description>300ug AZD5423 administered once daily in any of the first, second, third or fourth period of a particular sequence.</description>
        </group>
        <group group_id="E3">
          <title>Arm 3 - 2x200ug Budesonide</title>
          <description>2x200ug budesonide administered twice daily in any of the first, second, third or fourth period of a particular sequence.</description>
        </group>
        <group group_id="E4">
          <title>Arm 4 - Placebo</title>
          <description>Placebo administered in any of the first, second, third or fourth period of a particular sequence.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>VIRAL PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>SCRATCH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HELICOBACTER TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>DYSMENORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall not publish any results until (i) the date of the first Study results publication, or in case of a Multi-Centre Study the first Multi-Centre Results publication, agreed by the participating sites, and (ii) the end of the eighteen (18) month period following the completion or early termination of the Study at all participating sites.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Of the 27 patients enrolled, 20 (74.1%) patient were randomised to receive a treatment sequence consisting of 4 different treatment in random order. 19 patients completed each individual treatment period and 17 patients completed all 4 treatment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

